These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 19946587)
41. ST segment resolution in patients with tenecteplase-facilitated percutaneous coronary intervention versus tenecteplase alone: Insights from the Combined Angioplasty and Pharmacological Intervention versus Thrombolysis ALone in Acute Myocardial Infarction (CAPITAL AMI) trial. So DY; Ha AC; Davies RF; Froeschl M; Wells GA; Le May MR Can J Cardiol; 2010 Jan; 26(1):e7-12. PubMed ID: 20101370 [TBL] [Abstract][Full Text] [Related]
42. Drotrecogin alfa (activated) in an infant with gram-negative septic shock. Sajan I; Da-Silva SS; Dellinger RP J Intensive Care Med; 2004; 19(1):51-5. PubMed ID: 15035755 [TBL] [Abstract][Full Text] [Related]
43. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Bernard GR; Macias WL; Joyce DE; Williams MD; Bailey J; Vincent JL Crit Care; 2003 Apr; 7(2):155-63. PubMed ID: 12720562 [TBL] [Abstract][Full Text] [Related]
44. Drotrecogin alfa (activated). Lyseng-Williamson KA; Perry CM Drugs; 2002; 62(4):617-30; discussion 631-2. PubMed ID: 11893230 [TBL] [Abstract][Full Text] [Related]
45. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. Dhainaut JF; Yan SB; Joyce DE; Pettilä V; Basson B; Brandt JT; Sundin DP; Levi M J Thromb Haemost; 2004 Nov; 2(11):1924-33. PubMed ID: 15550023 [TBL] [Abstract][Full Text] [Related]
46. Sepsis-related acute kidney injury: a protective effect of drotrecogin alpha (activated) treatment? Janssen van Doorn K; Spapen H; Geers C; Diltoer M; Shabana W Acta Anaesthesiol Scand; 2008 Oct; 52(9):1259-64. PubMed ID: 18823466 [TBL] [Abstract][Full Text] [Related]
47. Low-dose, off-label drotrecogin alfa (xigris) in severe sepsis. Wang S; Dabovic K; Spector RS P T; 2008 Aug; 33(8):469-76. PubMed ID: 19750177 [TBL] [Abstract][Full Text] [Related]
48. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. Green C; Dinnes J; Takeda A; Shepherd J; Hartwell D; Cave C; Payne E; Cuthbertson BH Health Technol Assess; 2005 Mar; 9(11):1-126, iii-iv. PubMed ID: 15774234 [TBL] [Abstract][Full Text] [Related]
49. Obesity does not alter the pharmacokinetics of drotrecogin alfa (activated) in severe sepsis. Levy H; Small D; Heiselman DE; Riker R; Steingrub J; Chen R; Qualy RL; Darstein C; Mongan E Ann Pharmacother; 2005 Feb; 39(2):262-7. PubMed ID: 15632220 [TBL] [Abstract][Full Text] [Related]
50. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated). Micek ST; Isakow W; Shannon W; Kollef MH Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217 [TBL] [Abstract][Full Text] [Related]
52. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression. Kalil AC; LaRosa SP Lancet Infect Dis; 2012 Sep; 12(9):678-86. PubMed ID: 22809883 [TBL] [Abstract][Full Text] [Related]
53. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Laterre PF; Levy H; Clermont G; Ball DE; Garg R; Nelson DR; Dhainaut JF; Angus DC Crit Care Med; 2004 Nov; 32(11):2207-18. PubMed ID: 15640632 [TBL] [Abstract][Full Text] [Related]
54. Ischemic stroke complicating thrombolytic therapy with tenecteplase for ST elevation myocardial infarction: two case reports. Arous S; Haboub M; El Ghali Benouna M; Bentaoune T; Habbal R J Med Case Rep; 2017 Jun; 11(1):154. PubMed ID: 28601092 [TBL] [Abstract][Full Text] [Related]
56. Challenge and rechallenge: drotrecogin alfa (activated)-induced prolongation of activated partial thromboplastin time in a patient with severe sepsis. Castelli EE; Culley CM; Fink MP Pharmacotherapy; 2005 Aug; 25(8):1147-50. PubMed ID: 16207107 [TBL] [Abstract][Full Text] [Related]
57. Septic shock caused by Streptococcus pneumoniae in a post-splenectomy patient successfully treated with recombinant human activated protein C. Schumann C; Triantafilou K; Kamenz J; Hanke H; Triantafilou M; Wittemann S; Joos T; Hombach V; Schneider EM; Lepper PM Scand J Infect Dis; 2006; 38(2):139-42. PubMed ID: 16449010 [TBL] [Abstract][Full Text] [Related]
58. Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis? Friedrich JO; Adhikari NK; Meade MO Crit Care; 2006; 10(3):145. PubMed ID: 16762040 [TBL] [Abstract][Full Text] [Related]
59. ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis. Goldstein B; Nadel S; Peters M; Barton R; Machado F; Levy H; Haney DJ; Utterback B; Williams MD; Giroir BP Pediatr Crit Care Med; 2006 May; 7(3):200-11. PubMed ID: 16575354 [TBL] [Abstract][Full Text] [Related]
60. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Bernard GR; Margolis BD; Shanies HM; Ely EW; Wheeler AP; Levy H; Wong K; Wright TJ; Chest; 2004 Jun; 125(6):2206-16. PubMed ID: 15189943 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]